Galectin Therapeutics (GALT) Misses Q3 EPS by 6c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.26), $0.06 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Carvana (CVNA) PT Lowered to $85 at RBC Capital